Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)

Documenti analoghi

• Positive real-world effectiveness of tafamidis for delaying disease progression in transthyretin familial amyloid polyneuropathy
  di: Stewart, Michelle, et al.
  Pubblicazione: (2015)
• Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
  di: Li, Benjamin, et al.
  Pubblicazione: (2020)
• Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post-hoc analyses of a pivotal trial
  di: Keohane, Denis, et al.
  Pubblicazione: (2015)
• Tafamidis for a Transplant Patient with Transthyretin Amyloid Polyneuropathy
  di: Romero-Imbroda, Jesús, et al.
  Pubblicazione: (2017)
• Genotype and Phenotype of Transthyretin Cardiac Amyloidosis in the United States: The Transthyretin Amyloid Outcome Survey (THAOS)
  di: Maurer, Mathew S., et al.
  Pubblicazione: (2016)